|drug2134||Neuromuscular evaluation Wiki||1.00|
|drug3974||questionaire to husband and wife Wiki||1.00|
|D015673||Fatigue Syndrome, Chronic NIH||1.00|
There is one clinical trial.
Chronic fatigue is the most common and debilitating symptom in intensive care unit (ICU) survivors. Indeed, it has been widely reported that patients who stayed in ICU for prolonged periods report a feeling of tiredness for months to years after ICU discharge. This symptom seems particularly pronounced in Covid-19 patients and may affect their quality of life by decreasing their capacity to perform simple tasks of daily life. The aim of the present project is to determine whether deteriorated neuromuscular function (i.e. increased fatigability) is involved in the feeling of fatigue of Covid-19 patients. Because the causes of this feeling are multi-dimensional, a large battery of tests will allow us to better understand the origin of chronic fatigue. A better knowledge of chronic fatigue etiology and its recovery will allow to optimize rehabilitation treatments to shorten the persistence of chronic fatigue and in fine improve life quality.
Description: Level of cortical activation and cortico-spinal excitability measured by transcranial magnetic stimulationMeasure: Neuromuscular function : cortical activity Time: 6 weeks post-discharge
Description: Peripheral function by electrical nerve stimulationMeasure: Neuromuscular function : Peripheral function Time: 6 weeks post-discharge
Description: measured by effort testMeasure: Maximal oxygen uptake (VO2max) Time: 6 weeks post-discharge
Description: measured by actigraphyMeasure: quality of sleep Time: 6 weeks post-discharge
Description: with Magnetic resonance imagingMeasure: muscle volume Time: 6 weeks post-discharge
Description: measured by a Phosphorus 31 Nuclear magnetic resonance testMeasure: metabolic fatigue Time: 6 weeks post-discharge
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports